title: Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?
authors.forename: Rahil Alsadat
authors.initials: RA
authors.lastname: Shahtaheri
authors.forename: Afshin
authors.initials: A
authors.lastname: Borhani Haghighi
authors.forename: Anahid
authors.initials: A
authors.lastname: Safari
authors.forename: Salvador
authors.initials: S
authors.lastname: Cruz-Flores
mesh_terms: D003362:Cost-Benefit Analysis / Q000191:economics; D003906:Developing Countries / Q000191:economics*; D006748:Hospital Departments / Q000191:economics; D006801:Humans; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D010959:Tissue Plasminogen Activator / Q000191:economics* / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator